Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.
Kohsaka S, Tada Y, Ando M, Nakaguro M, Shirai Y, Ueno T, Kojima S, Hirai H, Saigusa N, Kano S, Tsukahara K, Togashi T, Ozawa H, Kondo T, Okami K, Takahashi H, Kawakita D, Fushimi C, Suzuki T, Shimizu A, Okamoto I, Okada T, Sato Y, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Urano M, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Shimura T, Nagao T, Mano H. Kohsaka S, et al. Among authors: yamazaki k. NPJ Precis Oncol. 2022 Nov 4;6(1):82. doi: 10.1038/s41698-022-00324-1. NPJ Precis Oncol. 2022. PMID: 36333410 Free PMC article.
Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan.
Matsuyama H, Yamazaki K, Okabe R, Ueki Y, Shodo R, Omata J, Sato Y, Ota H, Takahashi T, Tomita M, Yokoyama Y, Togashi T, Aoyama H, Abe E, Saijo Y, Katsura K, Soga M, Sugita T, Matsumoto Y, Tsuchida E, Horii A. Matsuyama H, et al. Among authors: yamazaki k. Auris Nasus Larynx. 2018 Oct;45(5):1086-1092. doi: 10.1016/j.anl.2018.02.008. Epub 2018 Mar 19. Auris Nasus Larynx. 2018. PMID: 29567334 Clinical Trial.
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.
Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, Fushimi C, Masubuchi T, Miura K, Okazaki SI, Matsui H, Okada T, Iwaki S, Matsuki T, Hanyu K, Tsukahara K, Oridate N, Tada Y. Niwa K, et al. Among authors: yamazaki k. Sci Rep. 2020 Oct 12;10(1):16988. doi: 10.1038/s41598-020-73965-6. Sci Rep. 2020. PMID: 33046752 Free PMC article.
3,250 results